The pathogenesis and prevention of joint damage in rheumatoid arthritis: Advances from synovial biopsy and tissue analysis

Arthritis and Rheumatism

Volumn 43, Issue 12, 2000, Pages 2619-2633

  Tak, Paul Peter ^a   Bresnihan, Barry ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CYTOKINE; GLUCOCORTICOID; GOLD DERIVATIVE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHOTREXATE; METHYLPREDNISOLONE; PENICILLAMINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANGIOGENESIS; APOPTOSIS; BONE ATROPHY; CARTILAGE; CARTILAGE DEGENERATION; CELL POPULATION; CLINICAL TRIAL; HUMAN; JOINT INJURY; MEDIATOR; PANNUS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIUM; TRANSCRIPTION REGULATION; TREATMENT OUTCOME;

ARTHRITIS, RHEUMATOID; BIOPSY; CARTILAGE, ARTICULAR; HUMANS; JOINT DISEASES; SYNOVIAL MEMBRANE;

EID: 0034545158     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200012)43:12<2619::AID-ANR1>3.0.CO;2-V     Document Type: Review

References (182)

1. Synovial tissue analysis in rheumatoid arthritis
2. Correlation of histopathologic features of pannus with patterns of damage in different joints in rheumatoid arthritis
3. Rheumatoid arthritis: Pathophysiology and implications for therapy
4. Electron microscopic studies of the cartilage-pannus junction in rheumatoid arthritis
5. Morphologic observations in the early phase of the cartilage-pannus junction: Light and electron microscopic studies of active cellular pannus
6. Histomorphologic basis of articular cartilage destruction in rheumatoid arthritis
7. The synovium-cartilage junction of the normal human knee: Implications for joint destruction and repair
8. Imaging
9. Pathogenesis of bone erosions in rheumatoid arthritis
10. Histopathology of the rheumatoid lesion: Identification of cell types at sites of cartilage erosion
11. Quantitative microscopic analysis of inflammation in rheumatoid arthritis synovial membrane samples selected at arthroscopy compared with samples obtained blindly by needle biopsy
12. Invasive fibroblast-like synoviocytes in rheumatoid arthritis: Passive responders or transformed aggressors?
13. Mononuclear phagocytes and rheumatoid synovitis: Mastermind or workhorse in arthritis?
14. Expression of myeloid related proteins (MRP) 8 and 14 and the MRP8/14 heterodimer in rheumatoid arthritis synovial membrane
15. Polymorphonuclear granulocytes at the pannus-cartilage junction in rheumatoid arthritis
16. Chondrocyte-derived cells and matrix at the rheumatoid cartilage-pannus junction identified with monoclonal antibodies
17. Cytokine control of interstitial collagenase and collagenase-3 gene expression in human chondrocytes
18. Pannocytes: Distinctive cells found in rheumatoid arthritis articular cartilage erosions
19. Characterisation of fibroblast-like cells in pannus lesions of patients with rheumatoid arthritis sharing properties of fibroblasts and chondrocytes
20. Mast cells at the site of cartilage erosion in the rheumatoid joint
21. Distribution, activation and tryptase/chymase phenotype of mast cells in the rheumatoid lesion
22. Mast cells, cytokines, and metalloproteinases at the rheumatoid lesion: Dual immunolocalisation studies
23. Localization of vascular growth factor in synovial membrane mast cells: Examination with 'multi-labelling subtraction immunostaining'
24. A new model for rheumatoid arthritis generated by engraftment of rheumatoid synovial tissue and normal human cartilage into SCID mice
25. Interleukin-1b-stimulated invasion of articular cartilage by rheumatoid synovial fibroblasts is inhibited by antibodies to specific integrin receptors and by collagenase inhibitors
26. Localisation of vitronectin receptor immunoreactivity and tartrate resistant acid phosphatase activity in synovium from patients with inflammatory or degenerative arthritis
27. Bone resorption by cells isolated from rheumatoid synovium
28. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis
29. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor
30. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
31. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
32. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis
33. Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis
34. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: Implications for the role of cytokines in joint destruction and repair
35. Interindividual and intra-articular variation of pro-inflammatory cytokines in rheumatoid arthritis patients: Potential implications for treatment
36. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis
37. Quantitative analysis of cytokine gene expression in rheumatoid arthritis
38. Localisation of interleukin-1a, type 1 interleukin receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis
39. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity
40. Expression of adhesion molecules in early rheumatoid synovial tissue
41. Analysis of the cellular infiltrates and expression of cytokines in synovial tissue from patients with rheumatoid arthritis and reactive arthritis
42. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis
43. Treatment of rheumatoid arthritis with a recombinant tumor necrosis factor receptor (p75)-Fc fusion protein
44. Transforming growth factor-beta 1 in rheumatoid synovial membrane and cartilage/pannus junction
45. Localisation of interleukin 8 in the synovial membrane, cartilage-pannus junction and chondrocytes in rheumatoid arthritis
46. Proteinases and matrix degradation
47. Collagenase at sites of cartilage erosion in the rheumatoid joint
48. Spontaneous expression of immediate-early response genes c-fos and egr-1 in collagenase-producing rheumatoid synovial fibroblasts
49. Comparative immunolocalisation studies of collagenase 1 and collagenase 3 production in the rheumatoid lesion, and by human chondrocytes and synoviocytes in vitro
50. Characterization of collagenase 3 (matrix metalloproteinase 13) messenger RNA expression in the synovial membrane and synovial fibroblasts of patients with rheumatoid arthritis
51. Cathepsin B in synovial cells at the site of joint destruction in rheumatoid arthritis
52. Macrophage cathepsin L, a factor in the erosion of subchondral bone in rheumatoid arthritis
53. Molecular cloning of human cDNA for cathepsin K: Novel cysteine proteinase predominantly expressed in bone
54. Cathepsin K, but not cathepsin B, L, or S, is abundantly expressed in human osteoclasts
55. Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction
56. Complement C1s activation in degenerating articular cartilage of rheumatoid arthritis patients: Immunohistochemical studies with an active form specific antibody
57. Newly identified actions of the vitamin D endocrine system
58. Interleukin-1a and b in growth plate cartilage are regulated by vitamin D metabolites
59. Vitamin D receptors in the rheumatoid lesion: Expression by chondrocytes, macrophages, and synoviocytes
60. Synthesis of the active metabolite of vitamin D,1,25(OH)2D3 by synovial fluid macrophages in arthritic diseases
61. Positive correlation between levels of IL-1 or IL-2 and 1,25(OH)2D/25OHD ratio in synovial fluids of patients with rheumatoid arthritis
62. Examination of the synovium and synovial fluid
63. Synovitis of recent onset: A clinicopathologic study during the first month of disease
64. Immunohistological features in the synovium obtained from clinically uninvolved knee joints of patients with rheumatoid arthritis
65. Synovitis occurs in some clinically normal and asymptomatic joints in patients with early arthritis
66. Asymptomatic synovitis precedes clinically manifest arthritis
67. Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis
68. Synovial tissue macrophages and joint erosion in rheumatoid arthritis
69. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis
70. Expression of the activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue
71. Tissue cytokine patterns distinguish variants of rheumatoid synovitis
72. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity
73. Collagenase-3 (MMP-13) and its activators in rheumatoid arthritis: Localization in the pannus-hard tissue junction and inhibition by alendronate
74. Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis
75. How important are T cells in chronic rheumatoid synovitis?
76. IFN-gamma and I,25(OH)2D3 induce on THP-1 cells distinct patterns of cell surface antigen expression, cytokine production, and responsiveness to contact with activated T cells
77. Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression
78. Evidence for the role of an altered redox state in hyporesponsiveness of synovial T cells in rheumatoid arthritis
79. An immunohistological analysis of lymphocyte subpopulations and their microenvironment in the synovial membranes of patients with rheumatoid arthritis using monoclonal antibodies
80. Presentation of self peptides by dendritic cells: Possible implications for the pathogenesis of rheumatoid arthritis
81. Differentiated dendritic cells expressing nuclear RelB are predominantly located in rheumatoid synovial tissue perivascular mononuclear cell aggregates
82. Selective infiltration of B cells committed to the production of monoreactive rheumatoid factor in synovial tissue of patients with rheumatoid arthritis
83. Rheumatoid factor production by mononuclear cells derived from different sites of patients with rheumatoid arthritis
84. Immunohistochemical analysis of proliferating and antigen-presenting cells in rheumatoid synovial tissue
85. Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis
86. Granzyme-positive cytotoxic cells are specifically increased in early rheumatoid synovial tissue
87. Demonstration of granzyme A and perforin messenger RNA in the synovium of patients with rheumatoid arthritis
88. The levels of soluble granzyme A and B are elevated in plasma and synovial fluid of patients with rheumatoid arthritis (RA)
89. Human granzyme B degrades aggrecan proteoglycan in matrix synthesized by chondrocytes
90. Destruction of articular cartilage by alpha 2 macroglobulin elastase complexes: Role in rheumatoid arthritis
91. Active matrix metalloproteinases are present in cartilage during immune complex-mediated arthritis: A pivotal role for stromelysin-1 in cartilage destruction
92. Mast cell responses in rheumatoid synovium: Association of the MC(TC) subset with matrix turnover and clinical progression
93. Synovial mast cell responses during clinical improvement in early rheumatoid arthritis
94. Signal transduction and transcription factors in rheumatic disease
95. Function and activation of NF-kB in the immune system
96. Nuclear factor-κB: A key role in inflammatory diseases
97. Efficient adenoviral infection with IκBα reveals that macrophage tumor necrosis factor α production in rheumatoid arthritis is NF-κB dependent
98. Nuclear factor-κB in rheumatoid synovium: Localization of p50 and p65
99. AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen induced arthritis
100. Direct evidence of high DNA binding activity of transcription factor AP-1 in rheumatoid arthritis synovium
101. Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue
102. Apoptosis in rheumatoid arthritis
103. Apoptosis in rheumatoid arthritis synovium
104. Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes
105. Ultrastructural demonstration of apoptosis, Fas and Bcl-2 expression of rheumatoid synovial fibroblasts
106. Localisation of apoptosis and expression of apoptosis related proteins in the synovium of patients with rheumatoid arthritis
107. Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis
108. NF-κB activation provides the potential link between inflammation and hyperplasia in the arthritic joint
109. Rheumatoid arthritis and p53: How oxidative stress might alter the course of inflammatory diseases
110. Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium
111. Mutations of the p53 tumour suppressor gene in erosive rheumatoid synovial tissue
112. Regulation of synoviocyte proliferation, apoptosis and invasion by the p53 tumor suppressor gene
113. p53 down-regulates human matrix metalloproteinase-1 (Collagenase-1) gene expression
114. Expression of sentrin, a novel antiapoptotic molecule, at sites of synovial invasion in rheumatoid arthritis
115. Contrasting levels of in vitro cytokine production by rheumatoid synovial tissue demonstrating different patterns of mononuclear cell infiltration
116. In situ hybridization of interleukin-1 in CD14-positive cells in rheumatoid arthritis
117. Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis
118. Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis
119. IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium
120. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis
121. Intraarticular variability of synovial membrane histology, immunohistology, and cytokine mRNA expression in patients with rheumatoid arthritis
122. IL-18: A Th1-inducing, proinflammatory cytokine and new member of the IL-1 family
123. Interleukin-18: A novel cytokine that augments both innate and acquired immunity
124. T cells cloned from human rheumatoid synovial membrane functionally represent the Th1 subset
125. A pro-inflammatory role for interleukin-18 in rheumatoid arthritis
126. Interleukin-18, rheumatoid arthritis, and tissue destruction
127. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis
128. Increased expression of IL-15 in the synovium of patients with rheumatoid arthritis compared to patients with Yersinia-induced arthritis and osteoarthritis
129. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor α production in rheumatoid arthritis
130. Cytokines and growth factors
131. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis
132. Immunolocalisation of matrix metalloproteinase 3 (stromelysin) in rheumatoid synovioblasts (B cells): Correlation with rheumatoid arthritis
133. Localization of collagenase mRNA in rheumatoid arthritis synovium by in situ hybridization histochemistry
134. Transin/stromelysin expression in rheumatoid synovium: A transformation-associated metalloproteinase secreted by phenotypically invasive synoviocytes
135. Stromelysin synthesizing cells in the synovial tissue of rheumatoid arthritis demonstrated by in situ hybridization and immnnohistochemical methods
136. In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium
137. Expression of metalloproteinases and metalloproteinase inhibitor in human arthritic synovium
138. Gene expression (collagenase, tissue inhibitor of metalloproteinases, complement, and HLA-DR) in rheumatoid arthritis and osteoarthritis synovium: Quantitative analysis and effect of intraarticular corticosteroids
139. Stromelysin and tissue inhibitor of metalloproteinase gene expression in rheumatoid arthritis synovium
140. Differential expression of gelatinase B (MMP-9) and stromelysin-1 (MMP-3) by rheumatoid synovial cells in vitro and in vivo
141. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis
142. Cloning of collagenase 3 from synovial membrane and its expression in rheumatoid arthritis and osteoarthritis
143. 342 site coincides with the initiation of collagen damage in murine antigen-induced arthritis: A pivotal role for stromelysin 1 in matrix metalloproteinase activity
144. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover
145. Comparative analysis of cathepsin L, cathepsin D, and collagenase messenger RNA expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis, by in situ hybridization
146. Differential expression of cathepsins B and L compared with matrix metalloproteinases and their respective inhibitors in rheumatoid arthritis and osteoarthritis: A parallel investigation by semiquantitative reverse transcriptase-polymerase chain reaction and immunohistochemistry
147. Nitric oxide and inflammatory joint diseases
148. Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients
149. Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritis
150. Immunolocalisation of inducible nitric oxide synthase in synovium and cartilage in rheumatoid arthritis and osteoarthritis
151. Cloning, characterization, and expression of a cDNA encoding an inducible nitric oxide synthase in human chondrocytes
152. Induction of nitric oxide synthase in human chondrocytes
153. Human articular chondrocytes induced by pro-inflammatory mediators are the major articular cell source of nitric oxide
154. Human osteoblast-like cells produce nitric oxide and express inducible nitric oxide synthase
155. Nitric oxide: A cytokine induced regulator of bone resorption
156. Nitric oxide and proteoglycan biosynthesis by human articular chondrocytes in alginate culture
157. Nitric oxide activates metalloprotease enzymes in articular cartilage
158. Chondrocyte apoptosis induced by nitric oxide
159. Angiogenesis: Implications for rheumatoid arthritis
160. Angiogenesis and arthritis
161. An investigation of the action of disease modifying antirheumatic drugs on the rheumatoid synovial membrane: Reduction in T lymphocyte subpopulations, and HLA-DP and DQ antigen expression after gold or penicillamine therapy
162. Changes in lymphocyte infiltration of the synovial membrane and the clinical course of rheumatoid arthritis
163. Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane
164. Methotrexate treatment reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis
165. The effects of drug therapy on radiographic progression of rheumatoid arthritis: Results of a 36-week randomized trial comparing methotrexate and auranofin
166. Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first antirheumatic drug
167. Mechanisms of methotrexate action in rheumatoid arthritis: Selective decrease in synovial collagenase gene expression
168. The effect of glucocorticoids on joint destruction in rheumatoid arthritis
169. Neutrophil trafficking into inflamed joints in patients with rheumatoid arthritis, and the effects of methylprednisolone
170. Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis
171. Gene expression (collagenase, tissue inhibitor of metalloproteinases, complement, and HLA-DR) in rheumatoid arthritis and osteoarthritis synovium: Quantitative analysis and effect of intraarticular corticosteroids
172. 54-week clinical and radiographic results from the ATTRACT trial: A phase III study of infliximab (Remicade) in patients with active RA despite methotrexate
173. Clinical improvement and radiological deterioration in rheumatoid arthritis: Evidence that the pathogenesis of synovial inflammation and articular erosion may differ
174. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis
175. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis
176. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis
177. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
178. Treatment of interleukin-1 receptor antagonist in combination with methotrexate (MTX) in rheumatoid arthritis (RA) patients
179. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of Genant and Larsen scoring methods
180. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis
181. The effects of interferon-beta treatment on arthritis
182. The effects of interferon-β treatment on synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis